260 related articles for article (PubMed ID: 20446233)
1. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
Hirt MN; Eschenhagen T
Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
[TBL] [Abstract][Full Text] [Related]
2. Vernakalant hydrochloride for the treatment of atrial fibrillation.
Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
4. Vernakalant in the management of atrial fibrillation.
Cheng JW
Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
[TBL] [Abstract][Full Text] [Related]
6. The pharmaceutical pipeline for atrial fibrillation.
Santangeli P; Di Biase L; Pelargonio G; Burkhardt JD; Natale A
Ann Med; 2011 Feb; 43(1):13-32. PubMed ID: 21166558
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
Stiell IG; Roos JS; Kavanagh KM; Dickinson G
Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
[TBL] [Abstract][Full Text] [Related]
8. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
Hinneburg I
Med Monatsschr Pharm; 2011 May; 34(5):154-8. PubMed ID: 21644373
[TBL] [Abstract][Full Text] [Related]
9. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Billman GE
Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
[TBL] [Abstract][Full Text] [Related]
10. Vernakalant. Too dangerous in atrial fibrillation.
Prescrire Int; 2012 May; 21(127):119-22. PubMed ID: 22827000
[TBL] [Abstract][Full Text] [Related]
11. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
[TBL] [Abstract][Full Text] [Related]
12. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
Conde D
Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
14. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
[TBL] [Abstract][Full Text] [Related]
15. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
Vizzardi E; Salghetti F; Bonadei I; Gelsomino S; Lorusso R; D'Aloia A; Curnis A
Cardiovasc Ther; 2013 Oct; 31(5):e55-62. PubMed ID: 23398692
[TBL] [Abstract][Full Text] [Related]
16. Vernakalant: A novel agent for the termination of atrial fibrillation.
Finnin M
Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
[TBL] [Abstract][Full Text] [Related]
17. Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.
Cialdella P; Pedicino D; Santangeli P
Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):1-8. PubMed ID: 21235460
[TBL] [Abstract][Full Text] [Related]
18. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
Ehrlich JR; Nattel S
Curr Opin Cardiol; 2009 Jan; 24(1):50-5. PubMed ID: 19077816
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
Savelieva I; Graydon R; Camm AJ
Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
